Dan Liu 1*, Biao Jin 2, Wei Chen 2 and Peng Yun 1
|
|
- Morris Oscar Newman
- 5 years ago
- Views:
Transcription
1 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 RESEARCH ARTICLE Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis Dan Liu 1*, Biao Jin 2, Wei Chen 2 and Peng Yun 1 Open Access Abstract Background: Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-dpp-4 inhibitor users. Methods: All English publications that compared the use of DPP-4 inhibitors and that reported cardiovascular outcomes in patients with T2DM were searched using specific terms. Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; The studies included a large sample size of participants; And they reported cardiovascular outcomes as their main endpoints. RevMan 5.3 was used to analyze the data, and odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results. Results: A total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the control group. Results of the current analysis showed that during a mean follow-up time period ranging from 52 to 152 weeks, the primary endpoint (cardiovascular death/non-fatal myocardial infarction (MI)/non-fatal stroke) was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: ; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: ; P = 0.93), stroke (OR: 1.03, 95% CI: ; P = 0.72), MI (OR: 0.97, 95% CI: ; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: ; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: ; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: ; P = 0.55) were also similarly manifested in both groups. Conclusion: The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicatingthatthosedrugsmightbesafetousein terms of cardiovascular events. Keywords: Dipeptidyl peptidase 4 inhibitors, Type 2 diabetes mellitus, Cardiovascular outcomes, Cardiovascular death * Correspondence: liudan315@163.com Dan Liu and Biao Jin contributed equally to this work. 1 Department of Endocrinology, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People s Republic of China Full list of author information is available at the end of the article The Author(s) Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 2 of 9 Background At present, even if all the patients with type 2 diabetes mellitus (T2DM) do not have the same risk, enough evidence is available regarding the occurrence of cardiovascular disease (CVD) in patients with long-standing uncontrolled T2DM [1]. Scientists are trying to develop oral hypoglycemic agents which while maintaining the blood sugar level to a constant level, could also reduce the rate of cardiovascular events. Recently, due to the fact that oral hypoglycemic drugs while significantly maintaining a normal blood glucose level, could paradoxically increase cardiovascular events in patients with T2DM [2], the Food and Drug Administration (FDA) ordered to demonstrate their safety prior to seeking approval. Because of this reason, several newer anti-diabetic agents have undergone randomized placebo-controlled cardiovascular outcome trials (CVOT) which mainly involved patients with preexisting CVD and patients who were at a higher risk of developing this serious chronic disease [3]. Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over the long-term (decent glycated hemoglobin [HbA1c]), and were not associated with hypoglycemia or weight gain in comparison to other similar drugs [4]. However, there was a need for a systematical evidence to show the impact of DPP-4 inhibitors on cardiovascular outcomes in such patients. In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-dpp-4 inhibitor users for the treatment of a large number of participants with T2DM. Methods Databases used during the search process The search process was carried out with reference to the PRISMA guideline [5]. Medical Literature Analysis and Retrieval System Online (MEDLINE) and its interface PubMed, biomedical and pharmacological bibliographic database Excerpta Medica database (EMBASE), Cochrane database and were searched for relevant publications. Search strategies and search terms All English publications that compared the use of DPP-4 inhibitors and reported cardiovascular outcomes in patients with T2DM were searched specifically using the terms: dipeptidyl peptidase 4 inhibitors and type 2 diabetes mellitus, dipeptidyl peptidase 4 inhibitors and diabetes mellitus and cardiovascular outcomes, dipeptidyl peptidase 4 inhibitors and cardiovascular outcomes, dipeptidyl peptidase 4 inhibitors and cardiac, DPP-4 inhibitors and diabetes mellitus. In addition, individual name of the drugs were also used: sitagliptin and type 2 diabetes mellitus, sitagliptin and cardiovascular outcomes, sitagliptin and diabetes mellitus and cardiovascular outcomes, saxagliptin and type 2 diabetes mellitus, saxagliptin and cardiovascular outcomes, saxagliptin and diabetes mellitus and cardiovascular outcomes, omarigliptin and type 2 diabetes mellitus, omarigliptin and cardiovascular outcomes, omarigliptin and diabetes mellitus and cardiovascular outcomes, alogliptin and type 2 diabetes mellitus, alogliptin and cardiovascular outcomes, alogliptin and diabetes mellitus and cardiovascular outcomes, linagliptin and cardiovascular outcomes, linagliptin and diabetes mellitus and cardiovascular outcomes, vildagliptin and cardiovascular outcomes, vildagliptin and diabetes mellitus and cardiovascular outcomes. Inclusion and exclusion criteria Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; They included a large sample size of participants (note that studies with very small sample size were excluded); They reported cardiovascular outcomes as their main endpoints; Studies were excluded if they consisted of the following features: They were literature reviews/meta-analyzes/case studies/letters to editors; They did not include DPP-4 inhibitor users for the treatment of patients with T2DM; They included a small sample size; They did not report cardiovascular outcomes as their endpoints; They were written in other languages than in English; They were duplicated studies. Type of DPP-4 inhibitors, cardiovascular outcomes reported and follow-up time periods Omarigliptin, sitagliptin, saxagliptin and alogliptin were the DPP-4 inhibitors which were used to treat these patients with T2DM as shown in Table 1. The following outcomes were assessed: Primary endpoint: consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke;
3 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 3 of 9 Table 1 Type of DPP-4 inhibitors, cardiovascular outcomes reported and follow-up time periods Studies Type of DPP-4 inhibitors Cardiovascular outcomes reported Gantz2017 [7] Omarigliptin Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular related death, fatal and nonfatal MI, fata and non-fatal stroke, all-cause mortality, hospitalization for heart failure, hospitalization for heart failure or cardiovascular death Green2015 [8] Park2015 [9] Scirica2013 [10] Shih2016 [11] Wang2015 [12] White2013 [13] Sitagliptin Unspecified DPP-4 inhibitors Saxagliptin Unspecified DPP-4 inhibitors Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, all-cause mortality All-cause mortality Cardiovascular death/non-fatal MI or non-fatal stroke, all-cause mortality, cardiovascular death, MI, stroke, hospitalization for unstable angina, hospitalization for heart failure, hospitalization for coronary revascularization All-cause mortality, MACEs, MI, stroke, heart failure Mean follow-up time period 96 weeks 152 weeks 124 weeks 109 weeks 114 weeks Sitagliptin Cardiovascular death/non-fatal MI or non-fatal stroke, MI, stroke, cardiovascular mortality 52 weeks Alogliptin Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular mortality, non-fatal MI, non-fatal stroke, all-cause mortality Abbreviations: DDP-4 Dipeptidyl peptidase 4, MI Myocardial infarction, MACEs Major adverse cardiac events Primary endpoint: including cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular related death, fatal and non-fatal MI 78 weeks Cardiovascular death; Myocardial infarction (MI); Stroke; All-cause mortality; Hospitalization for cardiovascular complications; Hospitalization specifically for heart failure. A mean follow-up time period ranging from 52 weeks to 152 weeks were considered relevant as shown in Table 1. Data extraction and quality assessment Four independent reviewers were responsible for the data extraction and quality assessment of the trials. In the beginning, each reviewer extracted the following data: the names of the authors, the year of publication, the type of DPP-4 inhibitors, the cardiovascular outcomes, the average follow-up time periods, the total number of participants from each group, the baseline features, the duration of diabetes mellitus, the total number of cardiovascular events; and at a later stage, data were compared and cross-checked to make sure all correct data were entered. Quality assessment of the trials was carried out with reference to the criteria suggested by the Cochrane Collaboration [6]. A maximum total score of 12 points was allotted based on the bias risk reported. Statistical analysis RevMan 5.3 software was used to carry out the statistical analysis of the pooled data. Odd ratios (OR) and 95% confidence intervals (CI) were generated to represent the main analytical data throughout the result section. Expected heterogeneity was assessed using the (1) Q statistic test whereby a result with a P value less or equal to 0.05 was considered statistically significant, and (2) the I 2 statistic test whereby a lower I 2 value denoted a lower heterogeneity. A fixed statistical effect model (I 2 < 50%) or a random statistical effect model (I 2 > 50%) was applied depending upon the value of heterogeneity which was generated. Sensitivity analysis was also carried out to compare with the main results for any significant difference by a method of exclusion. Since this analysis included only a very small volume of studies, publication bias was visually assessed through funnel plots which were generated through the RevMan software. Compliance with ethical guidelines This is a systematic review and meta-analysis of previously published original studies and therefore ethical approval or any board review approval was not required. Results Search outcomes Electronic search resulted in a total number of 4512 publications. An initial assessment was carried out to eliminate unwanted studies, and based on relevance, only 245 full-texts were finally assessed for eligibility. After another round of assessment, further eliminations were carried out based on the following criteria: Literature review/meta-analyses/case studies/letters to editors (n = 32); Cardiovascular outcomes were not reported (n = 22);
4 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 4 of 9 Consisted of a small number of participants (n = 49); Did not report the correct control group (n = 22); Duplicates (n = 113). Finally, only 7 studies (4 randomized controlled trials and 3 observational cohorts) [7 13] were selected for this analysis as shown in Fig. 1. Main features of the studies Four studies were randomized controlled trials and 3 studies were observational cohorts. A total number of 157, 478 participants with T2DM were included in this analysis. Seventy-six thousand and twenty six (76, 026) patients were assigned to the DPP-4 inhibitor group whereas 81, 452 patients were assigned to the control group as shown in Table 2. Patients were enrolled between the years 2007 to 2017 as shown in the Table. Based on the methodological assessment, a score ranging from 8 to 12 were allotted to the trials indicating a low to moderate risk of bias. Baseline features of the participants The baseline features of the participants have been listed in Table 3. As shown in the Table, a mean age of years were reported among the participants. Most of the participants were male patients with a mean percentage of %. The duration of diabetes mellitus varied from 7.10 to 12.1 years. The participants had an average HbA1c varying from 7.20 to 8.00 years. Other features which were reported in Table 3 included the percentage of participants with hypertension and current smoker. Analysis of the cardiovascular outcomes The current analysis showed that during a mean followup time period ranging from 52 weeks to 152 weeks, the primary endpoint was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: ; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: ; P =0.93), stroke (OR: 1.03, 95% CI: ; P =0.72), MI (OR: 0.97, 95% CI: ; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: ; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: ; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: ; P = 0.55) were also similarly manifested in both groups. The results have been represented in Figs. 2 and 3. Fig. 1 Flow diagram showing the study selection
5 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 5 of 9 Table 2 Main features of the studies Studies Type of study Time period of patients enrollment Total no of patients assigned to DPP-4 inhibitors (n) Gantz2017 [7] RCT Green2015 [8] RCT Park2015 [9] OS Scirica2013 [10] RCT Shih2016 [11] OS ,208 53,208 Wang2015 [12] OS White2013 [13] RCT Total no of patients (n) 76,026 81,452 Abbreviations: RCT Randomized controlled trials, OS Observational studies, DPP-4 dipeptidyl peptidase 4 Total no of patients assigned to control group (n) The main results have also been summarized in Table 4. Sensitivity analyses and publication bias Sensitivity analysis was carried out for the respective subgroups and consistent results were obtained throughout. When study Gantz2017 was excluded, results for primary endpoint (OR: 0.94, 95% CI: ; P = 0.25), cardiovascular death (OR: 0.99, 95% CI: ; P = 0.88), stroke (OR: 1.03, 95% CI: ; P = 0.66), MI (OR: 0.98, 95% CI: ; P =0.73), hospitalization for cardiovascular complications (OR: 1.03, 95% CI: ; P = 0.36), all-cause mortality (OR: 0.78, 95% CI: ; P = 0.18) and hospitalization specifically for heart failure (OR: 1.09, 95% CI: ; P = 0.20) were not significantly different compared to the main analysis. Consistent results were obtained throughout. When study Green2015 was excluded, results for primary endpoint (OR: 0.93, 95% CI: ; P = 0.14), cardiovascular death (OR: 0.95, 95% CI: ; P = 0.42), stroke (OR: 1.07, 95% CI: ; P = 0.48), MI (OR: 0.99, 95% CI: ; P = 0.86), hospitalization for cardiovascular complications (OR: 1.04, 95% CI: ; P = 0.28), all-cause mortality (OR: 0.80, 95% CI: ; P = 0.26) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: ; P = 0.69) were not significantly different compared to the main analysis. Consistent results were obtained throughout. Even when study Shih2016, which was the largest study (with the highest number of participants) in this analysis, when excluded, results for the primary endpoint (OR: 0.99, 95% CI: ; P =0.87),all-cause mortality (OR: 0.92, 95% CI: ; P = 0.48), hospitalization specifically for heart failure (OR: 1.01, 95% CI: ; P = 0.95), and hospitalization for cardiovascular complications (OR: 1.01, 95% CI: ; P = 0.80) were not significantly different compared to the main results of this current analysis, that is, still consistent results were obtained throughout. The same results were obtained even when the remaining studies were excluded by turn and new analyses were carried out. Also, a low evidence of publication bias was observed throughout, across all the trials and observational cohorts that assessed the cardiovascular outcomes between the DPP-4 inhibitor versus the non-dpp-4 inhibitor group as shown in Fig. 4. Table 3 Baseline features of the participants Studies Age (years) Males (%) Duration of DM (years) HbA1c (%) HBP (%) CS (%) DP/NDP DP/NDP DP/NDP DP/NDP DP/NDP DP/NDP Gantz / / / / / /14.5 Green2015 Park / / / /80.4 Scirica / / / / /82.4 Shih / / / /90.9 Wang / / /75.9 White / / / / / /14.3 Abbreviations: DM Diabetes mellitus, HbA1c Glycated hemoglobin, HBP High blood pressure, CS Current smoker, DP Dipeptidyl peptidase 4 inhibitor group, NDP Non-dipeptidyl peptidase 4 inhibitor group
6 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 6 of 9 Fig. 2 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 1) Discussion DPP-4 inhibitors are newer oral anti-diabetic agents with high expectations. Their mechanism of action is based on the prolongation of the activity of glucagon-like peptide 1 (GLP1), the gastric-inhibitory peptide, as well as other incretins by restraining their breakdown [14]. The current analysis which included a very large total number of participants showed that DPP-4 inhibitors were not associated with significantly higher cardiovascular outcomes in comparison to DDP-4 inhibitor non-users. Cardiovascular death, MI, hospitalization for cardiovascular complications and specifically for heart failure, were similarly manifested with DPP-4 inhibitors in these patients with T2DM. The SAVOR-TIMI 53 trial [10] which was a randomized, multicenter, double blind placebo-controlled phase 4 trial which demonstrated the cardiovascular safety and efficacy of DPP-4 inhibitors also did not show any increase in cardiovascular events associated with the use of this group of drugs. However, an increased rate of hospitalization due to heart failure was observed. In the EXAMINE trial [13], whereby 5380 participants underwent randomization, the authors concluded that no increase in adverse cardiovascular events were
7 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 7 of 9 Fig. 3 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 2) observed in those patients who were recently affected by acute coronary syndrome. Even in the TECOS trial [8], which was also a randomized, double-blind study involving more than 10, 000 participants, the authors did not observe any significant increase in cardiovascular outcomes with the use of DPP-4 inhibitors for the treatment of patients with T2DM. However, compared to the SAVOR-TIMI 53 trial, there was no increase in hospitalization due to heart failure in the TECOS trial. Another open observational non-crossover retrospective cohort study which was conducted between June 2012 and December 2013, and which compared the cardiovascular efficacy and safety of linagliptin, Table 4 Results of this analysis with a large population size Cardiovascular outcomes assessed No of studies involved (n) OR with 95% CI P value I 2 value (%) Primary endpoint [ ] Cardiovascular death [ ] All-cause mortality [ ] Stroke [ ] Myocardial infarction [ ] Hospitalization for cardiovascular complications [ ] Hospitalization specifically for heart failure [ ] Abbreviations: OR Odds ratios, CI Confidence intervals
8 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 8 of 9 Fig. 4 Funnel plot representing publication bias another DPP-4 inhibitor, also did not show any significant increase in cardiovascular events with the drug in these patients with T2DM and acute coronary syndrome [15]. However, the forthcoming CARMELINA trial which aimed to demonstrate the effects of linagliptin on cardiovascular and renal outcomes might further add information to DPP-4 inhibitors and cardiovascular events [16]. Limitations First of all, the inclusion of data which were extracted from observational studies have increased the heterogeneity during subgroup analysis. This might be one major limitation of this analysis. Secondly, the duration of T2DM was not similar in all the studies. In addition, the follow-up time periods were different in different studies, and this might have affected the results. Also, different DPP-4 inhibitors were combined prior to analysis and this might have also contributed to the limitations observed in this analysis. Conclusions The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events. Abbreviations CVD: Cardiovascular diseases; DPP-4: Dipeptidyl peptidase 4; OR: Odds ratios; T2DM: Type 2 diabetes mellitus Acknowledgements All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
9 Liu et al. BMC Pharmacology and Toxicology (2019) 20:15 Page 9 of 9 Funding No funding or sponsorship was received for this study or publication of this article. Availability of data and materials All data and materials used in this research are freely available in electronic databases. References have been provided. Authors contributions DL, BJ, WC and PY were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. DL and BJ wrote the final draft of the manuscript. DL, BJ, WC and PY approved the final manuscript as it is. DL and BJ are co-first authors. Ethics approval and consent to participate Ethical approval was not applicable for this systematic review and metaanalysis. Consent for publication Not applicable. Competing interests The authors Dr. Dan Liu, Dr. Biao Jin, Dr. Wei Chen, and Dr. Peng Yun declare that they have no competing interests. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author details 1 Department of Endocrinology, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People s Republic of China. 2 Department of Critical Care Medicine, Jingzhou First Peoples Hospital, Jingzhou, Hubei, People s Republic of China. Received: 11 January 2019 Accepted: 26 February 2019 References 1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics update: a report from the American Heart Association. Circulation. 2017;135(10):e Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593): Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med. 2013;369(14): Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardio-metabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116(8): Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b Higgins JP, et al. Assessing risk of bias in included studies. In: Cochrane handbook for systematic reviews of interventions: Wiley; p Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1): Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3): Park HE, Jeon J, Hwang IC, Sung J, Lee SP, Kim HK, Cho GY, Sohn DW, Kim YJ. Effect of dipeptidyl Peptidase-4 inhibitor on all-cause mortality and coronary Revascularizationin diabetic patients. J Cardiovasc Ultrasound. 2015;23(4): Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14): Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT. Cardiovascular outcomes of dipeptidyl Peptidase-4 inhibitors in elderly patients with type 2 diabetes: a Nationwide study. J Am Med Dir Assoc. 2016;17(1): Wang SH, Chen DY, Lin YS, Mao CT, Tsai ML, Hsieh MJ, Chou CC, Wen MS, Wang CC, Hsieh IC, Hung KC, Chen TH. Cardiovascular outcomes of Sitagliptin in type 2 diabetic patients with acute MyocardialInfarction, a population-based cohort study in Taiwan. PLoS One. 2015;10(6):e White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14): Krishna R, Addy C, Tatosian D, Glasgow XS, Gendrano Iii IN, Robberechts M, Haazen W, de Hoon JN, Depré M, Martucci A, Peng JZ, Johnson-Levonas AO, Wagner JA, Stoch SA. Pharmacokinetics and pharmacodynamics of Omarigliptin, a once-weekly dipeptidyl Peptidase-4 (DPP-4) inhibitor, after single and multiple doses in healthy subjects. J Clin Pharmacol. 2016;56(12): Li YR, Tsai SS, Chen DY, Chen ST, Sun JH, Chang HY, Liou MJ, Chen TH. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovasc Diabetol. 2018;17(1): Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA investigators. Rationale, design, and baseline characteristics of the CArdiovascular safety and renal microvascular outcome study with LINAgliptin (CARMELINA ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17(1):39.
Supplementary Online Content
Supplementary Online Content McGuire DK, Van de Werf F, Armstrong PW, et al; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart
More informationHeart Disease and Stroke Statistics 2018 At-a-Glance
Heart Disease and Stroke Statistics 2018 At-a-Glance Here are a few key statistics about heart disease, stroke, other cardiovascular diseases and their risk factors, in addition to commonly cited statistics
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationEffects of Paroxetine on Mortality and Hospital Admissions in Heart Failure Patients
Effects of Paroxetine on Mortality and Hospital Admissions in Heart Failure Patients MARIE ANN NGAN, PHARM.D. OKLAHOMA CITY VA HEALTH CARE SYSTEMS PGY1 PHARMACY RESIDENT APRIL 8, 2016 Disclosure Statement
More informationPravesh Kumar Bundhun 1, Girish Janoo 2, Abhishek Rishikesh Teeluck 2 and Feng Huang 3*
Bundhun et al. BMC Pharmacology and Toxicology (2017) 18:66 DOI 10.1186/s40360-017-0175-0 RESEARCH ARTICLE Open Access Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationSupplementary Text A. Full search strategy for each of the searched databases
Supplementary Text A. Full search strategy for each of the searched databases MEDLINE: ( diabetes mellitus, type 2 [MeSH Terms] OR type 2 diabetes mellitus [All Fields]) AND ( hypoglycemia [MeSH Terms]
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
The new england journal of medicine Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D.,
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationThe delicate balance of disease
Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes Vani P. Sanon, MD, Saurabh Sanon, MD, Son V. Pham, MD, FACC, and Robert Chilton, DO, FACC The delicate
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim
DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim Endocrinology of Metabolism, Korea University College of Medicine Conflict of interest disclosure None
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationSitagliptin and heart failure hospitalization in patients with type 2 diabetes
/, Vol. 7, No. 38 Sitagliptin and heart failure hospitalization in patients with type 2 diabetes Chin-Hsiao Tseng 1,2,3 1 Department of Internal Medicine, National Taiwan University College of Medicine,
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationOBJECTIVE RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS. Diabetes Care Volume 39, July CARDIOVASCULAR AND METABOLIC RISK
Diabetes Care Volume 39, July 2016 1267 Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial Diabetes Care 2016;39:1267 1273 DOI: 10.2337/dc16-0303
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationINEQUALITY REPORT American Heart Association.
INEQUALITY REPORT 1 Heart Disease Remains the Leading Cause of Death Among Women: Disparities by Race/ Ethnicity Every 79 seconds, a woman in the United States (US) dies from heart disease or stroke. That
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationA nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD
The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Udell JA, Cavender MA, Bhatt DL, Chatterjee
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationDPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety
Perspective DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety Francesco Paneni Cardiology Unit, Department of Medicine, Karolinska University Hospital, Solna, Stockholm, Sweden Correspondence
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationType 2 diabetes affects an estimated 25.8 million
Hosp Pharm 2014;49(8):697 701 2014 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj4908-697 Cardiovascular Therapeutics Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationSupplementary Online Content
Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes.
More informationImpatto dei farmaci antidiabetici sullo scompenso cardiaco
Impatto dei farmaci antidiabetici sullo scompenso cardiaco Riccardo Candido S.S.D. Gestione Rete Diabetologica Aziendale Azienda Sanitaria Universitaria Integrata di Triste Il sottoscritto Riccardo Candido
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationNuo Li, Ye-Gui Yang and Meng-Hua Chen *
Li et al. BMC Cardiovascular Disorders (2016) 16:238 DOI 10.1186/s12872-016-0422-0 RESEARCH ARTICLE Open Access Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes
More informationCARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale.
CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS Mugdha Gokhale A dissertation submitted to the faculty at the University of North Carolina
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationEfficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Diabetes Ther (2018) 9:1995 2014 https://doi.org/10.1007/s13300-018-0493-2 ORIGINAL RESEARCH Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationABSTRACT ORIGINAL RESEARCH. Xia Dai. Zu-chun Luo. Lu Zhai. Wen-piao Zhao. Feng Huang
Diabetes Ther (2018) 9:753 770 https://doi.org/10.1007/s13300-018-0399-z ORIGINAL RESEARCH Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION
https://doi.org/10.1186/s12933-019-0835-z Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Dipeptidyl peptidase 4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationReview Article The role of systemic sclerosis on the coronary artery disease risk: a systematic review and meta-analysis
Int J Clin Exp Med 2017;10(9):13009-13014 www.ijcem.com /ISSN:1940-5901/IJCEM0042007 Review Article The role of systemic sclerosis on the coronary artery disease risk: a systematic review and meta-analysis
More informationFeng Huang. Huang BMC Pharmacology and Toxicology (2018) 19:31
Huang BMC Pharmacology and Toxicology (2018) 19:31 https://doi.org/10.1186/s40360-018-0224-3 RESEARCH ARTICLE Open Access Stent thrombosis associated with drug eluting stents on addition of cilostazol
More informationEffective Health Care Program
Comparative Effectiveness Review Number 173 Effective Health Care Program Diabetes Medications for Adults With Type 2 Diabetes: An Update Executive Summary Condition and Therapeutic Strategies Type 2 diabetes
More information10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer
Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials Eckhard Leifke, MD PhD Senior Medical Director Takeda Global Research Development Center, Inc. Presentation
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationRESEARCH. Shanil Ebrahim, 7, 10, 12, 13 German Malaga, 14 Lorena P Rios, 15 Yingqiang Wang, 16 Qunfei Chen, 17 Gordon H Guyatt, 7, 18 Xin Sun 1
open access Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies Ling Li, 1 Sheyu Li, 2 Ke Deng, 3
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationAlogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
original article after Acute Coronary Syndrome in Patients with Type 2 Diabetes William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven E. Nissen, M.D., Richard M. Bergenstal,
More informationObesity and T2DM trials
Obesity and T2DM trials Dr Alexander Miras Senior Clinical Lecturer Endocrinology Look AHEAD NEJM 2013 LOOK AHEAD trial - weight loss for diabetes with and without cardiovascular disease Look AHEAD NEJM
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationLong-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
www.nature.com/scientificreports Received: 11 October 2016 Accepted: 16 June 2017 Published online: 25 July 2017 OPEN Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES
More informationsurgery: A systematic review and meta-analysis protocol
Title Perioperative dexmedetomidine and outcomes after adult cardiac surgery: A systematic review and meta-analysis protocol Registration PROSPERO (registered December 8 th, 2015) Authors David McIlroy
More informationReview Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
Diabetes Research Volume 2016, Article ID 1643496, 7 pages http://dx.doi.org/10.1155/2016/1643496 Review Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS Samit
More information2016 Georgia Society of Health-System Pharmacists Summer Meeting CV Risk Factors: Emerging Data on Management of Type 2 Diabetes and Hypertension
2016 Georgia Society of Health-System Pharmacists Summer Meeting CV Risk Factors: Emerging Data on Management of Type 2 Diabetes and Hypertension Jeff Langford, PharmD BCPS Clinical Pharmacy Specialist,
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,
More informationGUIDANCE UPDATE TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL.
TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL GUIDANCE UPDATE cpd credits Production of this Guidelines supplement has been funded by an educational
More informationDiabetes and the Heart
Diabetes and the Heart By Samir Naim Assaad, MD, MRCP(UK), FRCP(Edin), FRCP(Lond) Professor of Medicine & Endocrinology University of Alexandria EGYPT Disclosure None, related to this presentation Road
More informationHeart Disease and Stroke Statistics-2019 At-a-Glance
Heart Disease and Stroke Statistics-2019 At-a-Glance This document contains a few key statistics about heart disease, stroke, other cardiovascular diseases and their risk factors, in addition to commonly
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationThe updated incidences and mortalities of major cancers in China, 2011
DOI 10.1186/s40880-015-0042-6 REVIEW Open Access The updated incidences and mortalities of major cancers in China, 2011 Wanqing Chen *, Rongshou Zheng, Hongmei Zeng and Siwei Zhang Abstract Introduction:
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationSGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? David Preiss, 3 John J McMurray 1
SGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar, 1 James McLaren, 1 Søren L Kristensen, 2 David Preiss, 3 John J McMurray 1 1 Institute
More informationReal World Evidence: From Efficacy to Effectiveness
Real World Evidence: From Efficacy to Effectiveness Professor Kamlesh Khunti University of Leicester, UK Leicester Diabetes Centre at University Hospitals of Leicester NHS Trust, 2015. Not to be reproduced
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationReflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft
1 2 3 21 May 2015 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular
More informationSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Diabetologia (2016) 59:1333 1339 DOI 10.1007/s00125-016-3956-x REVIEW SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar 1
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationPravesh Kumar Bundhun 1, Chandra Mouli Yanamala 2 and Wei-Qiang Huang 1*
Bundhun et al. BMC Cardiovascular Disorders (2017) 17:84 DOI 10.1186/s12872-017-0515-4 RESEARCH ARTICLE Open Access Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More information